Supreme Court to Weigh In on Gene Patents

more+
less-

On April 15, 2013, the U.S. Supreme Court heard arguments in Association for Molecular Pathology (AMP) v. Myriad Genetics, Inc. At issue is the eligibility of Myriad’s patent claims to isolated DNA encoding BRCA1 polypeptides. Individuals who inherit a mutated BRCA1 gene have an increased chance of developing certain cancers, particularly breast and ovarian cancers. The U.S. Court of Appeals for the Federal Circuit ruled that Myriad’s claims to isolated DNA molecules qualify as patent-eligible compositions of matter under 35 U.S.C. § 101.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

more+
less-

Banner & Witcoff, Ltd. on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×